Nalaganje...

Management of myelofibrosis after ruxolitinib failure

Myelofibrosis is a BCR-ABL1–negative myeloproliferative neoplasm characterized by anemia, progressive splenomegaly, extramedullary hematopoiesis, bone marrow fibrosis, constitutional symptoms, leukemic progression, and shortened survival. Constitutive activation of the Janus kinase/signal transducer...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Hematol
Main Authors: Harrison, Claire N, Schaap, Nicolaas, Mesa, Ruben A
Format: Artigo
Jezik:Inglês
Izdano: Springer Berlin Heidelberg 2020
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237516/
https://ncbi.nlm.nih.gov/pubmed/32198525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-020-04002-9
Oznake: Označite
Brez oznak, prvi označite!